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ABSTRACT
Monoclonal B-cell lymphocytosis (MBL) is a recently described medical condition that displays biological similarities to the most common subtype of 
adult leukemia in the Western world, i.e. chronic lymphocytic leukemia (CLL). Diagnostic criteria have been published with the aim of differentiating 
between these two entities. The overall prevalence of MBL is at least 100 times higher than that of CLL, which indirectly suggests that MBL is not 
necessarily a pre-leukemic condition, although in some circumstances, CLL cases can really be preceded by MBL. In view of this high prevalence rate, 
general clinicians and even non-hematological specialists have a high chance of being faced with individuals with MBL in their routine clinical practice. 
MBL is classified as “clinical MBL”, “population-screening MBL” and “atypical MBL” and the clinical management of affected individuals depends 
greatly on this differentiation. The present review provides a guide to diagnosing and following up MBL patients. 
RESUMO 
A linfocitose monoclonal de células B (LMB) é uma condição médica recentemente descrita que exibe similaridades biológicas com o mais comum 
subtipo de leucemia em adultos de países ocidentais, qual seja, a leucemia linfocítica crônica (LLC). Critérios diagnósticos foram publicados com o 
intuito de separar as duas entidades. A prevalência global da LMB é pelo menos 100 vezes maior do que a da LLC, o que, indiretamente, sugere que a 
LMB não é necessariamente uma condição pré-leucêmica, embora, em algumas circunstâncias, casos de LLC possam realmente ser precedidos pela 
LMB. Em virtude dessa alta taxa de prevalência, clínicos gerais e mesmo outros especialistas não hematologistas têm grande chance de deparar-se 
com casos de LMB em suas rotinas clínicas. A LMB é classificada como “LMB clínica”, “LMB de screening populacional” e “LMB atípica”, sendo que 
o manuseio clínico dos indivíduos afetados depende substancialmente dessa diferenciação. A presente revisão fornece um guia para o diagnóstico 
e acompanhamento dos pacientes com LMB.
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DEFINITION AND HISTORY 
Over the last few years, the more widespread availability of au-
tomated blood cell counters, associated with increasing technological 
advances in flow cytometry, has made it possible to recognize very low 
levels of circulating monoclonal B-lymphocytes that are immunophe-
notypically similar to chronic lymphocytic leukemia B-cells, in the 
peripheral blood of healthy subjects. Within this scenario, general cli-
nicians and even non-hematological specialists have a high chance of 
coming across asymptomatic individuals with slight increases in abso-
lute lymphocyte counts, composed of abnormal B-cell clones, in pe-
ripheral blood, but without the diagnostic criteria for chronic lympho-
cytic leukemia (CLL).1
The first published paper to describe these abnormal B-cells dates 
back to 1991, consisting of a report from a health study conducted by 
the Centers for Disease Control (CDC) in the United States, which 
detected monoclonal B-cells in people living near hazardous waste 
sites. In 1995, a public health service workshop in the United States 
put forward recommendations for case definitions and medical fol-
low-up.2 Subsequently, over the next ten years, an increasing number 
of studies on different populations around the world, using different 
flow cytometry approaches, recognized that CD5+ and CD5− mono-
clonal B-lymphocytes could be found in individuals with no clinically 
apparent hematological disease.3
In 2005, the International Familial CLL Consortium proposed the 
term “monoclonal B-cell lymphocytosis” (MBL) to describe very low 
levels of circulating monoclonal B-cells that were identified by means 
of immunophenotypic characterization, in the peripheral blood of ap-
parently health subjects. Furthermore, diagnostic criteria for this con-
dition were defined and, with little modification, these continue to be 
used today (Chart 1).4
EPIDEMIOLOGY
The overall prevalence of MBL is at least 100 times higher than 
that of CLL, which indirectly suggests that MBL is not necessarily 
a pre-leukemic condition, but may represent an aspect of immu-
nosenescence or the outcome from persistent immune stimulation 
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(discussed later in “Biology and natural history of MBL”).5 More-
over, the prevalence of MBL is age-related and population-related. 
Rawstron et al.6 showed that the overall prevalence of CLL-like MBL 
among United Kingdom hospital outpatients without hematological 
or oncological diseases and with normal blood counts was 3.5%. The 
prevalence increased with age, from 2.1% in individuals between 40 
and 60 years of age to 5.0% for individuals over 60 years of age. Ghia 
et al.7 studied individuals from a rural community referred for rou-
tine blood tests and showed that the overall prevalence was 5.1%. In 
a recent study conducted in a community in northern Italy, Dagk-
lis et al.8 reported that the prevalence of CLL-like MBL and atypical 
MBL was 6.3%. The prevalence in individuals over 60 years of age 
was 8.9%. Other published papers have found different prevalence 
rates going from as low as 0.14%9 to as high as 12.0%,10  but this 
wide variation is probably related to the use of different flow cytom-
etry approaches, i.e. other than the most commonly used four-color 
flow cytometry method. This hampers comparisons between these 
studies at the present time.
With regard to population subgroups, the highest prevalence of 
CLL-like MBL has been found in healthy first-degree relatives of pa-
tients with familial CLL, which is a condition characterized by the pres-
ence of two or more individuals with the diagnosis of CLL inside the 
same family.11 Thus, Rawstron et al.12 detected the presence of MBL in 
eight out of 59 individuals (13.5%) pertaining to 21 families with CLL 
in the United Kingdom. The prevalence in another study on 9 families 
with CLL in the United States was 18%.13 These studies clearly show 
that MBL is more frequently observed in CLL kindreds than in individ-
uals from the general population.
Lastly, using the worldwide four-color flow cytometry approach, 
we have recently studied 167 healthy first-degree relatives of patients 
with just one case of CLL inside the family (sporadic CLL). We found 
seven CLL-like MBL cases (overall prevalence of 4.1%). However, the 
prevalence of individuals over 60 years of age was 15.6%, which sug-
gests that in older first-degree relatives of patients with sporadic CLL, 
the risk of MBL detection is as high as in older first-degree relatives 
from CLL families.14 Nonetheless, at this moment, there is no evi-
dence to suggest that searches for MBL should be conducted in first-
degree relatives of patients with the diagnosis of CLL. However, it is 
recommended that relatives who are potential donors for allogeneic 
stem cell transplantation should be screened for MBL, mainly because 
the transplanted monoclonal B-cells could interfere with the residual 
disease monitoring performed by flow cytometry and, moreover, there 
is a possibility of expansion of the MBL clone in the recipient.4 Nev-
ertheless, there is currently no consensus on whether or not matched 
relatives should be excluded, especially when there are no alternative 
donors inside the family.15
BIOLOGY AND NATURAL HISTORY OF MBL
With regard to the phenotype determined by flow cytometry, 
monoclonal B-cell lymphocytosis has been classified as MBL with 
CLL-like phenotype, MBL with atypical CLL phenotype and MBL 
with non-CLL phenotype (Chart 1). Moreover, MBL can also be clas-
sified as cases detected in clinical practice (clinical MBL), in which in-
dividuals have absolute lymphocytosis, but with B-cell counts lower 
than 5 x 109 cells/l, or otherwise, MBL cases accidentally found by 
screening individuals with a completely normal blood count (popula-
tion-screening MBL).15
Chart 1. Diagnostic criteria and subclassification for monoclonal B-cell 
lymphocytosis (adapted from Shanafelt et al.)15
DIAGNOSTIC CRITERIA
(1) Detection of a monoclonal B-cell population in the peripheral blood* by at least 
one of following:
(a) Light-chain restriction: overall kappa:lambda ratio > 3:1 or < 0.3:1, or > 25% of 
B cells lacking or expressing low levels of surface immunoglobulin†
(b) Heavy-chain monoclonal immunoglobulin heavy chain variable region (IGHV) 
rearrangements
(2) Presence of a disease-specific immunophenotype†,‡
(3) Absolute B-cell count < 5 x 109 cells/l†
(4) No other features of a lymphoproliferative disorder:
(a) Normal physical examination (no lymphadenopathy or organomegaly)
(b) Absence of B-symptoms (fever, weight loss or nighttime sweating) attributable to 
a non-Hodgkin lymphoma
(5) No autoimmune or infectious disease
SUBCLASSIFICATION
(A) CLL-like phenotype: 
(A.1) Coexpression of CD5 with CD19, CD20low and CD23†
(A.2) Light-chain restriction with low surface immunoglobulin expression (very small 
MBL clones may be oligoclonal and thus not light-chain restricted)†
(B) Atypical CLL phenotype:
(B.1) Coexpression of CD5 with CD19, but CD20strong or CD23 negative†
(B.2) Light-chain restriction with moderate/strong surface immunoglobulin expression†
(B.3) Exclude t(11;14) to rule out mantle cell lymphoma
(C) Non-CLL phenotype :
(C.1) CD5 negative†
(C.2) Expression of  CD20†
(C.3) Light-chain restriction with moderate/strong surface immunoglobulin expression†
*When possible, a repeat assessment should demonstrate that MBL is stable over a three-month period; 
†Defined by flow cytometry; ‡A disease-specific immunophenotype is an abnormal B-cell phenotype that sepa-
rates it from normal B-cells. The most common disease-specific immunophenotype is the presence of CD5+ 
B-lymphocytes with abnormally low expression of CD20 antigen.
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MBL with CLL-like phenotype accounts for most cases8 and ex-
hibits a population of monoclonal B-cells that, in addition to CD5 and 
CD23 positivity, show low expression of CD20 and CD79b antigens. 
This profile is phenotypically identical to CLL B-cells.16 Moreover, the 
biological similarities of MBL with CLL-like and CLL phenotypes are 
demonstrable through other levels of scientific evidence: first, the pro-
tein expression profile is almost identical between them and, second, 
some chromosomal abnormalities frequently found in CLL patients are 
also present in individuals with CLL-like MBL.16 However, despite this 
biological relationship, a recent paper by Rossi et al.17 showed that MBL 
and CLL are clinically different conditions, given that individuals with 
MBL have a more favorable clinical course than do patients with the di-
agnosis of Rai 0 CLL.
With regard to clinical progression, Rawstron et al.18 followed up 185 
subjects with clinical MBL for more than six years (median follow-up pe-
riod of 6.7 years) and showed that CLL requiring treatment developed 
at a rate of 1.1% per year, mainly in subjects with clinical MBL, which 
is similar to the rate of progression to myeloma seen in patients with 
monoclonal gammopathy of undetermined significance. On the other 
hand, although limited data are available, progression among individuals 
with population-screening MBL is rarely seen in the practice of authors 
at different centers with wide experience of the management of MBL.18 
Moreover, new studies are providing compelling evidence that not only 
the clinical characteristics but also the biology of population-screening 
MBL differ from that of clinical MBL. Thus, Dagklis et al.8 have shown 
that the usage of immunoglobulin heavy chain variable region (IGHV) is 
different between clinical and population-screening MBL, which means 
that the two conditions are probably biologically distinct entities. 
Hence, it is possible to infer that individuals with population-
screening MBL are unlikely to be at any substantially higher risk of 
developing CLL than observed among the general population.18 This 
means that, in a general manner, MBL is not necessarily a pre-malig-
nant condition. This conception is reinforced by studies showing that 
although MBL was originally thought to be exclusively monoclonal, 
both oligoclonal19 and polyclonal8,14 cases have been described. Thus, 
MBL can now be considered to be an entity with three possible differ-
ent outcomes (Figure 1). 
In this context, the distinction between a malignant and a premalig-
nant condition is best made based on the individual’s risk of an adverse 
clinical outcome.20 Currently, only B-cell counts in peripheral blood can 
be used to make a distinction among patients with monoclonal B-cells 
with regard to the necessity of starting some kind of therapy in the 
light of a risk of death. Thus, at the present time, only limited data 
are available for ascertaining whether prognostic factors classically asso-
ciated with CLL outcomes, as determined by flow cytometry (CD38, 
CD49d and ZAP-70), cytogenetics (del 17 and del 11q) or molecular 
biology methods (IGHV rearrangement), can be used to predict the risk 
of MBL progression.
DIAGNOSIS EVALUATION AND CLINICAL 
MANAGEMENT
The differential diagnosis between MBL, CLL and another related 
condition known as small lymphocytic lymphoma is based on periph-
eral blood B-cell counts and physical examinations on patients. MBL is 
characterized by an absolute peripheral blood B-cell count lower than 
5 x 109 cells/l and absence of lymphadenopathy and hepatosplenomeg-
aly. Small lymphocytic lymphoma is also characterized by an absolute 
peripheral blood B-cell count lower than 5 x 109 cells/l, but the pres-
ence of lymph nodes, liver or spleen enlargement is typical of this dis-
ease. CLL is defined by the presence of more than 5 x 109 B-cells/l in pe-
ripheral blood. Lymphadenopathy and hepatosplenomegaly are found 
to varying degrees in patients with CLL (Table 1).15 Patients with a di-
agnosis of CLL, small lymphocytic lymphoma, clinical CLL-like MBL 
or atypical/non-CLL-like MBL should undergo a complete evaluation 
by a hematologist. 
The clinical management for individuals with MBL differs accord-
ing to whether the patient presents population-screening MBL, clinical 
CLL-like MBL or atypical/non-CLL-like MBL. In practical terms, gen-
eral clinicians should follow up individuals with population-screening 
MBL, given that these individuals have completely normal blood count 
and, in particular, that clinical experience has shown that progression in 
this group is very rare. For such individuals, close monitoring is not nec-
essary and an annual examination with a complete blood count is suf-
ficient and appropriate.15
As previously stated, patients with clinical CLL-like MBL have a risk 
of progression to CLL requiring treatment that is 1.1% per year.18 Based 
on this low risk, an annual follow-up with a complete blood count made 
by a hematologist is recommended. These patients should be counseled 
to pay attention to specific symptoms such as lymph node enlargement, 
nighttime sweating, extreme fatigue and weight loss, given that these 
clinical findings could be the first evidence of disease progression.
MBL
Persistency
Progression to CLL or other
lymphoproliferative disorder
Regression
Figure 1. Possible outcomes from monoclonal B-cell lymphocytosis (MBL).
MBL = monoclonal B-cell lymphocytosis; CLL = chronic lymphocytic leukemia.
Table 1. Differential diagnosis: monoclonal B-cell lymphocytosis (MBL), 
small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia 
(CLL) (adapted from Shanafelt et al. )15
Peripheral blood B-cells 
count < 5 x 109/l
Lymphadenopathy or 
hepatosplenomegaly
MBL Yes No
SLL Yes Yes
CLL No Yes or No
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Patients with atypical or non-CLL-like MBL require a more thor-
ough evaluation. In cases of lymph node enlargement found by com-
puted tomography scans, these patients are best classified as having a 
non-Hodgkin lymphoma subtype, which should be subclassified based 
on complementary examinations (immunohistochemistry, cytogenetics 
etc). For such individuals, close clinical and laboratory monitoring is 
mandatory. Table 2 summarizes the recommendations for evaluation 
and follow-up of MBL in routine practice.
CONCLUSIONS
Monoclonal B-cell lymphocytosis is a very common clinical con-
dition that is frequently found in asymptomatic subjects. It is biologi-
cally related to chronic lymphocytic leukemia and, in some cases, can 
be found prior to the diagnosis of CLL, although, at the present time, 
MBL cannot necessarily be considered to be a pre-leukemic condition. 
The prevalence of MBL is at least 100 times higher than that of 
CLL. Thus, given that both availability of automated blood cell coun-
ters and access to flow cytometry tests are more widespread nowadays, it 
is not surprising that clinicians may unexpectedly find MBL cases dur-
ing their daily practice. Within this scenario, it is important to recognize 
situations in which patients with a diagnosis of MBL can be followed 
up in general clinicians’ offices, versus situations in which they must be 
referred to a hematologist.
For diagnostic purposes, monoclonal B-cell lymphocytosis should 
be distinguished from chronic lymphocytic leukemia and small lym-
phocytic lymphoma. Moreover, it is essential to classify individual cases 
as “population-screening MBL” or “clinical MBL” and, furthermore, 
based on immunophenotyping, as “MBL with CLL-like phenotype”, 
“MBL with atypical CLL phenotype” or “MBL with non-CLL pheno-
type”, given that the clinical management for these patients is strongly 
dependent on this classification. 
LITERATURE SEARCH
We conducted a search in the literature regarding MBL in the five 
databases, using the term monoclonal B-cell lymphocytosis, and limit-
ing the search to papers published in English over the last 20 years, in-
cluding all types of articles (clinical trials, editorials, letters, meta-anal-
yses, practical guidelines or randomized controlled trials). Articles with 
relevant information about the epidemiological, biological and clinical 
aspects of MBL have been included in the reference list of this paper. 
The results from the search are shown in Table 3.
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